Skip to main content
Top
Published in: Rheumatology International 8/2006

01-06-2006 | Original Article

Association of macrophage migration inhibitory factor gene −173 G/C polymorphism with prognosis in turkish children with juvenile rheumatoid arthritis

Authors: Afig Berdeli, Arif Ruhi Özyürek, Zülal Ülger, Dolunay Gürses, Ertürk Levent, Koray Salar, Ali Rahmi Gürpınar

Published in: Rheumatology International | Issue 8/2006

Login to get access

Abstract

The objectives of this study were to determine genotypic and allelic frequencies of macrophage migration inhibitory factor (MIF) gene −173 G/C polymorphism in patients with juvenile rheumatoid arthritis (JRA) and to evaluate the association of the MIF −173 C allele with the outcome of JRA. Genomic DNA was collected from 67 JRA patients and 153 healthy individuals. To evaluate the association of the MIF −173 polymorphism with the outcome, we analyzed the data concerning the treatment regimen, duration of glucocorticoid treatment, score on the childhood health assessment questionnaire (C-HAQ) and the number of joints with active arthritis. Nonsignificant differences were observed between the study and control groups in the distribution of genotype and allele frequencies of the MIF gene −173 G/C polymorphism. In JRA patients, carrying a MIF −173 C allele, the number of disease modifying antirheumatic drugs required for the treatment was more, the duration of glucocorticoid treatment was significantly longer, and at the last visits the C-HAQ scores and the number of joints with active arthritis were significantly higher. MIF gene −173 C allele frequency did not differ between the controls and JRA patients. MIF −173 C allele did not confer increased susceptibility to JRA in our study group. Carriage of the MIF −173 C allele was found to be a strong predictor of poor outcome in all types of JRA.
Literature
1.
go back to reference Brewer EJ, Bass J, Baum J et al (1977) Current proposed revision of JRA criteria. Arthritis Rheum 20:195–199PubMed Brewer EJ, Bass J, Baum J et al (1977) Current proposed revision of JRA criteria. Arthritis Rheum 20:195–199PubMed
3.
go back to reference Swope MD, Lolis E (1999) Macrophage migration inhibitory factor: cytokine, hormone or enzyme. Rev Physiol Biochem Pharmacol 139:1–32PubMedCrossRef Swope MD, Lolis E (1999) Macrophage migration inhibitory factor: cytokine, hormone or enzyme. Rev Physiol Biochem Pharmacol 139:1–32PubMedCrossRef
4.
go back to reference De Benedetti F, Meazza C, Vivarelli M, Rossi Federice, Pistorio A, Lamb R, Lunt M, Thomson W, the British Paediatric Rheumatology Study Group, Ravelli A, Rachelle Donn, Martini A (2003) Functional and prognostic relevance of the −173 polymorphism of the macrophage migration inhibitory factor gene in systemic onset juvenile idiopathic arthritis. Arthritis Rheum 48:1398–1407PubMedCrossRef De Benedetti F, Meazza C, Vivarelli M, Rossi Federice, Pistorio A, Lamb R, Lunt M, Thomson W, the British Paediatric Rheumatology Study Group, Ravelli A, Rachelle Donn, Martini A (2003) Functional and prognostic relevance of the −173 polymorphism of the macrophage migration inhibitory factor gene in systemic onset juvenile idiopathic arthritis. Arthritis Rheum 48:1398–1407PubMedCrossRef
5.
go back to reference Donnelly SC, Bucala R (1997) Macrophage migration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflammatory disease. Mol Med Today 3:502–507PubMedCrossRef Donnelly SC, Bucala R (1997) Macrophage migration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflammatory disease. Mol Med Today 3:502–507PubMedCrossRef
6.
go back to reference Meazza C, Pignatti P, Magni-Manzoni S, Martini A, de Benedetti F (2000) Increased levels of macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis Rheum 43:356CrossRef Meazza C, Pignatti P, Magni-Manzoni S, Martini A, de Benedetti F (2000) Increased levels of macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis Rheum 43:356CrossRef
7.
go back to reference Berdeli A, Mir S, Ozkayin N, Serdaroglu E, Tabel Y, Cura A (2005) Association of macrophage migration inhibitory factor −173 C allele polymorphism with steroid resistance in children with nephritic syndrome. Pediatr Nephrol (in press) Berdeli A, Mir S, Ozkayin N, Serdaroglu E, Tabel Y, Cura A (2005) Association of macrophage migration inhibitory factor −173 C allele polymorphism with steroid resistance in children with nephritic syndrome. Pediatr Nephrol (in press)
8.
go back to reference Baugh JA, Chitnis S, Donnelly SC, Monteiro J, Lin X, Plant BJ, Wolfe F, Gregersen PK, Bucala R (2002) A functional promoter polymorphism of macrophage migration inhibitory factor gene associated with disease severity in rheumatoid arthritis. Genes Immun 3:170–176PubMedCrossRef Baugh JA, Chitnis S, Donnelly SC, Monteiro J, Lin X, Plant BJ, Wolfe F, Gregersen PK, Bucala R (2002) A functional promoter polymorphism of macrophage migration inhibitory factor gene associated with disease severity in rheumatoid arthritis. Genes Immun 3:170–176PubMedCrossRef
9.
go back to reference Donn R, Alourfi Z, De Benedetti F, Meazza C, Zeggini E, Lunt M et al (2002) Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile rheumatoid arthritis. Arthritis Rheum 46:2402–2409PubMedCrossRef Donn R, Alourfi Z, De Benedetti F, Meazza C, Zeggini E, Lunt M et al (2002) Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile rheumatoid arthritis. Arthritis Rheum 46:2402–2409PubMedCrossRef
10.
go back to reference Petty RE, Southwood TR, Baum J, Bhettay E, Glass E, Glass DN, Manners P et al (1998) Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban J Rheumatol 25:1991–1994 Petty RE, Southwood TR, Baum J, Bhettay E, Glass E, Glass DN, Manners P et al (1998) Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban J Rheumatol 25:1991–1994
11.
go back to reference Dempster H, Porepa M, Young N, Feldman BM (2001) The clinical meaning of functional outcome scores in children with juvenile arthritis. Arthritis Rheum 44:1768–1774PubMedCrossRef Dempster H, Porepa M, Young N, Feldman BM (2001) The clinical meaning of functional outcome scores in children with juvenile arthritis. Arthritis Rheum 44:1768–1774PubMedCrossRef
12.
go back to reference Fantini F, Gerloni V, Gattinara M et al (1996) Remission in juvenile chronic arthritis: a cohort study in 506 consecutive cases. American College of Rheumatology, 60th National Meeting October 17–22, Orlando FL Fantini F, Gerloni V, Gattinara M et al (1996) Remission in juvenile chronic arthritis: a cohort study in 506 consecutive cases. American College of Rheumatology, 60th National Meeting October 17–22, Orlando FL
13.
go back to reference Spiegel LR, Schneider R, Lang BA, Birdi N, Silverman ED, Laxer RM, et al (2000) Early predictors of poor functional outcome in systemic onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum 43:2402–2409PubMedCrossRef Spiegel LR, Schneider R, Lang BA, Birdi N, Silverman ED, Laxer RM, et al (2000) Early predictors of poor functional outcome in systemic onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum 43:2402–2409PubMedCrossRef
14.
go back to reference Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M et al (1996) An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 93:7849–7854PubMedCrossRef Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M et al (1996) An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 93:7849–7854PubMedCrossRef
15.
go back to reference Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T et al (1995) MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377:68–71PubMedCrossRef Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T et al (1995) MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377:68–71PubMedCrossRef
16.
go back to reference Gäre BA (1999) Juvenile arthritis: who gets it, where and when? A review of current data on incidence and prevalence. Clin Exp Rheumatol 17:367–374 Gäre BA (1999) Juvenile arthritis: who gets it, where and when? A review of current data on incidence and prevalence. Clin Exp Rheumatol 17:367–374
17.
go back to reference Peterson LS, Mason T, Nelson AM, O’Fallon WM, Gabriel SE (1997) Psychosocial outcomes and health status of adults who have had juvenile rheumatoid arthritis: a controlled, population-based study. Arthritis Rheum 40:2235–2240PubMedCrossRef Peterson LS, Mason T, Nelson AM, O’Fallon WM, Gabriel SE (1997) Psychosocial outcomes and health status of adults who have had juvenile rheumatoid arthritis: a controlled, population-based study. Arthritis Rheum 40:2235–2240PubMedCrossRef
18.
go back to reference Baugh JA, Bucala R (2002) Macrophage migration inhibitory factor. Crit Care Med 30:27–35CrossRef Baugh JA, Bucala R (2002) Macrophage migration inhibitory factor. Crit Care Med 30:27–35CrossRef
19.
go back to reference Lolis E (2001) Glucocorticoid counterregulation: macrophage migration inhibitory factor as a target for drug discovery. Curr Opin Pharmacol 1:662–668PubMedCrossRef Lolis E (2001) Glucocorticoid counterregulation: macrophage migration inhibitory factor as a target for drug discovery. Curr Opin Pharmacol 1:662–668PubMedCrossRef
20.
go back to reference De Jong YP, Abadia-Molina Ac, Satoskar AR, Clarke K, Rietdijk ST, Faubion WA et al (2001) Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2:1061–1066PubMedCrossRef De Jong YP, Abadia-Molina Ac, Satoskar AR, Clarke K, Rietdijk ST, Faubion WA et al (2001) Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2:1061–1066PubMedCrossRef
21.
go back to reference Kitaichi N, Kotake S, Sasamoto Y, Namba K, Matsuda A, Ogasawara K, et al (1999) Development of macrophage migration inhibitory factor in the sera of patients with uveitis. Invest Ophtalmol Vis Sci 40:247–250 Kitaichi N, Kotake S, Sasamoto Y, Namba K, Matsuda A, Ogasawara K, et al (1999) Development of macrophage migration inhibitory factor in the sera of patients with uveitis. Invest Ophtalmol Vis Sci 40:247–250
22.
go back to reference Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M et al (1999) Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 42:1601–1608PubMedCrossRef Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M et al (1999) Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 42:1601–1608PubMedCrossRef
23.
go back to reference Brown FG, Nikolic-Paterson DJ, Hill PA, Isbel NM, Dowling J, Metz CM et al (2002) Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis. J Am Soc Nephrol 13:7–13 Brown FG, Nikolic-Paterson DJ, Hill PA, Isbel NM, Dowling J, Metz CM et al (2002) Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis. J Am Soc Nephrol 13:7–13
24.
go back to reference Niino M, Ogata A, Kikuchi S, Tashiro K, Nishihira J (2000) macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro_Behçet’s disease. J Neurol Sci 179:127–131PubMedCrossRef Niino M, Ogata A, Kikuchi S, Tashiro K, Nishihira J (2000) macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro_Behçet’s disease. J Neurol Sci 179:127–131PubMedCrossRef
25.
go back to reference Donn RP, Shelley E, Ollier WER, Thomson W, and the British Pediatric Rheumatology Study Group (2001) A novel 5′, flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 44:1782–1785 Donn RP, Shelley E, Ollier WER, Thomson W, and the British Pediatric Rheumatology Study Group (2001) A novel 5′, flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 44:1782–1785
26.
27.
go back to reference Gregersen PK, Bucala R (2003) Macrophage migration inhibitory factor, MIF alleles, and the genetics of inflammatory disorders: incorporating disease outcome into the definition of phenotype. Arthritis Rheum 48:1171–1176PubMedCrossRef Gregersen PK, Bucala R (2003) Macrophage migration inhibitory factor, MIF alleles, and the genetics of inflammatory disorders: incorporating disease outcome into the definition of phenotype. Arthritis Rheum 48:1171–1176PubMedCrossRef
Metadata
Title
Association of macrophage migration inhibitory factor gene −173 G/C polymorphism with prognosis in turkish children with juvenile rheumatoid arthritis
Authors
Afig Berdeli
Arif Ruhi Özyürek
Zülal Ülger
Dolunay Gürses
Ertürk Levent
Koray Salar
Ali Rahmi Gürpınar
Publication date
01-06-2006
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 8/2006
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-005-0062-7

Other articles of this Issue 8/2006

Rheumatology International 8/2006 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.